Cancer Nanotheranostics: What Have We Learned So Far?
Frontiers Media SA, 2016
Online
Monographie, Elektronische Ressource
- 1 electronic resource (128 p.)
Ermittle Ausleihstatus...
After a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for mechanisms of treatment will follow closely. It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. In fact, the National Cancer Institute predicts that over the next years, nanotechnology will result in important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, prevention and control of cancer.-
Nanotechnology offers numerous tools to diagnose and treat cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells. Nanomaterials-based delivery systems in Theranostics (Diagnostics & Therapy) provide better penetration of therapeutic and diagnostic substances within the body at a reduced risk in comparison to conventional therapies. At the present time, there is a growing need to enhance the capability of theranostics procedures where nanomaterials-based sensors may provide for the simultaneous detection of several gene-associated conditions and nanodevices with the ability to monitor real-time drug action.-
These innovative multifunctional nanocarriers for cancer theranostics may allow the development of diagnostics systems such as colorimetric and immunoassays, and in therapy approaches through gene therapy, drug delivery and tumor targeting systems in cancer. Some of the thousands and thousands of published nanosystems so far will most likely revolutionize our understanding of biological mechanisms and push forward the clinical practice through their integration in future diagnostics platforms. Nevertheless, despite the significant efforts towards the use of nanomaterials in biologically relevant research, more in vivo studies are needed to assess the applicability of these materials as delivery agents. In fact, only a few went through feasible clinical trials. Nanomaterials have to serve as the norm rather than an exception in the future conventional cancer treatments.-
Titel: |
Cancer Nanotheranostics: What Have We Learned So Far?
|
---|---|
Autor/in / Beteiligte Person: | Tian, Furong ; Fuente, Jesus M. De La ; Baptista, Pedro Viana ; Conde, Joao |
Lokaler Link: | |
Link: | |
Veröffentlichung: | Frontiers Media SA, 2016 |
Medientyp: | Monographie |
Datenträgertyp: | Elektronische Ressource |
Umfang: | 1 electronic resource (128 p.) |
ISBN: | 9782889197767 |
Schlagwort: |
|
Sonstiges: |
|